Vanda Atypical Antipsychotic Shows Apparent Genetic Response In Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Study of iloperidone in schizophrenics meets its primary endpoint and also included a genetic profiling evaluation.
You may also be interested in...
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
Vanda Submits NDA For Antipsychotic Iloperidone
Firm says if schizophrenia treatment is approved, a favorable safety profile will differentiate the product from competitors.